Bionano Genomics (NASDAQ:BNGO) just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is getting leaner while its technology goes deeper into the clinical mainstream.
- BNGO stock is soaring. See the chart and price action here.
Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday’s regular session.
The Financials: Narrowing the Gap
For the fourth quarter, Bionano reported revenue of $8 million, landing at the high end of its previous guidance. While this was a 3% decrease from the prior year, the real victory was in the margins. Full-year gross margins skyrocketed to 46%, a massive leap from the 1% seen in 2024.
The improvement stems from a strategic shift toward recurring revenue. …